PCM
ARQT icon

Penn Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Penn Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-333,130
Closed -$7.86M – 187
2026
Q1 		$7.86M Buy
+333,130
New +$8.5M 0.61% 74

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Penn Capital Management's ARQT Position: Q2 2026 in Review

Penn Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 333,130 shares — an estimated $7.86M sold.

Penn Capital Management first reported a position in ARQT in Q1 2026 and held it in 1 quarter. The position peaked at $7.86M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Penn Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Penn Capital Management sold 333,130 Arcutis Biotherapeutics shares in Q2 2026, an estimated $7.86M.
  • Penn Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Penn Capital Management's Arcutis Biotherapeutics position peaked at $7.86M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.